Collaboration will explore complementary technologies and expertise to accelerate the development of next-generation, in vivo engineered cell therapies for difficult-to-treat solid tumors
CellantraTech, a biotechnology company focused on [brief company description], today announced that it has signed a cooperation memorandum with Capstan to explore the development of next-generation in vivo CAR-T therapies for solid tumors.
The collaboration is intended to combine the companies’ complementary scientific and technological capabilities to address key challenges that have historically limited the effectiveness and scalability of CAR-T therapies in solid tumors.
Under the cooperation memorandum, the parties plan to explore areas including CAR design and optimization, tumor-target selection, in vivo immune-cell programming and delivery, tumor-microenvironment biology, and preclinical evaluation of potential therapeutic candidates. Specific programs, development responsibilities, intellectual-property arrangements and future commercialization rights will be governed by subsequent agreements, as applicable.
Unlike conventional CAR-T approaches that require immune cells to be collected from a patient, genetically engineered outside the body and subsequently reinfused, in vivo CAR-T approaches seek to program immune cells directly within the patient. The companies believe this approach has the potential to create a more streamlined and scalable path for developing engineered cell therapies while enabling new strategies for tackling the biological complexity of solid tumors.
Thomas Wong, Chief Technology Officer of CellantraTech, said:
“Solid tumors remain one of the most important and technically demanding frontiers for CAR-T therapy. We believe that bringing cell engineering directly into the body could open new possibilities for how these therapies are designed, manufactured and ultimately delivered to patients. Through this collaboration with Capstan, we aim to combine complementary expertise in CAR engineering, tumor biology and in vivo delivery to develop innovative approaches capable of overcoming some of the fundamental barriers presented by solid tumors. This memorandum represents an important step toward translating that scientific vision into potential new therapies for patients.”
The collaboration will initially focus on establishing technical feasibility and identifying opportunities where the partners’ respective technologies can create differentiated therapeutic approaches. Potential candidates emerging from the collaboration will be subject to further preclinical evaluation and, where appropriate, additional development agreements.
The cooperation reflects a shared interest in expanding the potential of engineered immune-cell therapies beyond current treatment paradigms and developing technologies that could make cell therapy more programmable, scalable and applicable to a broader range of cancers.
About CellantraTech
CellantraTech is a [clinical-stage/preclinical-stage] biotechnology company developing [company technology/platform description]. The company is focused on [key therapeutic areas and mission]. Through its proprietary [platform name] platform, [Company Name] seeks to develop next-generation therapies for patients with cancers and other serious diseases.
For more information, visit [website].
About the Collaboration
The cooperation memorandum establishes a framework for scientific and technical collaboration between the parties. The memorandum does not, unless otherwise specified in the definitive agreement, represent the initiation of a clinical trial or imply regulatory approval of any product candidate. Additional details regarding individual development programs may be announced as they progress.
Forward-Looking Statements
This press release contains forward-looking statements regarding the anticipated collaboration, research activities and potential development of in vivo CAR-T therapies. These statements involve risks and uncertainties, and actual results may differ materially from those expressed or implied. Any product candidates discussed remain subject to research, preclinical and clinical development and applicable regulatory review.
Media Contact
[Name]
[Title]
CellantraTech
Email: [email]
Phone: [phone]
